Nathan Beahm
nathanbeahm.bsky.social
Nathan Beahm
@nathanbeahm.bsky.social
Associate Clinical Professor, University of Alberta. Academic Pharmacist. Infectious Diseases, Antimicrobial Stewardship, Pain Management.
We don't have cefdinir in Canada, which I must say is quite nice.
October 25, 2025 at 7:02 PM
TID more commonly
January 29, 2025 at 2:45 PM
Good question. I believe in Hanson's with ENL, the higher daily dose is used for its perceived anti-inflammatory effects. But agreed, the optimal dosing of clofazimine in general is a bit of a mystery. A nice discussion on this from earlier this year here:
doi.org/10.1093/jac/...
Why do we use 100 mg of clofazimine in TB and NTM treatment?
Abstract. Current tuberculosis and non-tuberculous mycobacterial disease guidelines recommend the use of clofazimine in a 100 mg once-daily dose. The ratio
doi.org
December 13, 2024 at 4:50 PM
Agreed!
December 12, 2024 at 8:12 PM
At this time, I'm not sure what types of patients this could be useful for. Small study, mostly looking at feasibility and tolerance; effectiveness metrics not captured. But interesting, nonetheless!
December 12, 2024 at 8:10 PM
I'm sure the dogma won't die that easily (do they ever?), but certainly a great step in that direction!
November 20, 2024 at 9:11 PM
Same here, it seems to be tolerated reasonably well. Similar to 500 mg TID, which has the same amount of clav, of course.
November 19, 2024 at 5:56 AM
Several of us in Edmonton will do amox/clav 875 mg po TID in an attempt to strike a balance between optimizing PK/PD and patient convenience.
November 18, 2024 at 4:46 PM